IONS Ionis Pharmaceuticals, Inc.

46.35
-0.20  -0%
Previous Close 46.55
Open 47.20
Price To book 28.58
Market Cap 5.75B
Shares 123,965,000
Volume 986,823
Short Ratio 4.90
Av. Daily Volume 1,855,160

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b initiation announced March 30, 2017.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
Phase 1/2 ongoing
IONIS-DMPK-2.5Rx
Myotonic Dystrophy Type 1 (DM1)
Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns.
IONIS-TTRRx
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease
Phase 3 data released March 6, 2017 - primary endpoint met. Relative safety concerns noted.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 3 initiated November 2015
Volanesorsen
Partial lipodystrophy rapidly
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Phase 3 initiated November 2015
Volanesorsen
Familial partial lipodystrophy (FPL)
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
IONIS-TTRRx
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.

Latest News

  1. Biogen's Fampyra Conditional Approval Converted to Standard
  2. Akcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects
  3. Pharma Stock With Triple-Digit Growth Forming Blotchy Base
  4. Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IONS-US : May 19, 2017
  5. Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal
  6. Ionis (IONS) Stock Falls Despite Positive Inotersen Data
  7. Want to Get in on Biotech? Check Out These 3 Stocks
  8. Blog Coverage: Ionis Pharma Reported Positive Phase III Results in Patients with Familial Amyloid Polyneuropathy
  9. Today's Research Reports on Stocks to Watch: Ionis Pharmaceuticals and Exact Sciences Corporation
  10. How Ionis Helped Rival Alnylam — But Tanked Itself — On A Key Trial
  11. Safety Concerns Ding Ionis
  12. Why Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today
  13. Here's Why Shares of Ionis Pharma (IONS) are Falling Today
  14. Why Ionis Pharma Is Sinking Despite Solid Late-Stage Results
  15. Biotech Movers: Ionis, Alnylam, Amicus, Minerva
  16. Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
  17. Edited Transcript of IONS earnings conference call or presentation 9-May-17 3:30pm GMT
  18. Ionis Pharmaceuticals Inc.'s First Royalties Roll In
  19. Ionis Pharmaceuticals Provides Corporate Update at 2017 Annual Meeting of Stockholders
  20. Alnylam Pharmaceuticals, Inc. Earnings: All Eyes on APOLLO